Hypercortisolism on the background of recovery of COVID-19 (сase report)

Authors

  • V. Kravchenko State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine”, Kyiv, Ukraine
  • O. Rakov State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine”, Kyiv, Ukraine
  • L.V. Slipachuk Bohomolets National Medical University, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0721.18.2.2022.1159

Keywords:

Cushing’s syndrome, hypercortisolism, COVID-19, treatment, case report

Abstract

Damage to the lung tissue is a predominant complication of the viral disease COVID-19. Recently, there have been complications from other organs, including highly vascularized endocrine glands. Regarding the adrenal glands, there are reports of their damage with a decrease in their function. Сhanging the function of the adrenal glands (AG) in patients with or after COVID-19 is important. A few adrenal autopsy studies in patients have revealed vascular thrombosis, cortical lipid degeneration, ischemic necrosis, parenchymal infarcts, and other lesions leading to a decrease in AG function. The central mechanism of adrenal dysfunction through hemorrhage and necrosis of the pituitary gland is also possible. This paper presents a rare case of the development of hypercortisolism in a young woman after recovering from COVID-19. Based on high ACTH levels (157 and 122 pg/ml), a negative nocturnal dexamethasone test, and high 24-hour urinary free (daily) cortisol excretion rates, we tentatively suspected Cushing’s disease. Chromogranin A was within the normal range of 21.35 (reference value < 100). Other tests showed an elevated dihydrotestosterone level of 780.6 pg/ml (reference values 24–368 pg/ml). The levels of other anterior pituitary hormones tested were within the normal range. According to clinical guidelines, the drug of choice for the short-term treatment of this disease is steroidogenesis inhibitors — ketoconazole. The effectiveness of such a treatment regimen was previously brought to light by others. In our case, ketoconazole was prescribed at a dose of 400 mg 2 times a day and cabergoline (dostinex) at an initial dose of 1 mg per day. Given the low levels of vitamin D in the blood serum, it was recommended to continue taking vitamin D at a dose of 4000 IU per day. It was recommended to control blood laboratory parameters — serum cortisol, ACTH, AST, ALT, electrolytes, 25(OH)D, blood glucose level after 2 months and decide on further tactics for managing the patient.

Downloads

Download data is not yet available.

References

WHO. Weekly operational update on COVID-19 - 22 February 2022. https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19-22-february-2022 .

Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003 Jul;200(3):282-9. doi: 10.1002/path.1440.

Guo Y, Korteweg C, McNutt MA, Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res. 2008 Apr;133(1):4-12. doi: 10.1016/j.virusres.2007.01.022.

Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006 Jun;23(6):623-8. doi: 10.1111/j.1464-5491.2006.01861.x.

Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020 May-Jun;14(3):211-212. doi: 10.1016/j.dsx.2020.03.002.

Ippolito S, Dentali F, Tanda ML. SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report. J Endocrinol Invest. 2020 Aug;43(8):1171-1172. doi: 10.1007/s40618-020-01312-7.

Asfuroglu Kalkan E, Ates I. A case of subacute thyroiditis associated with Covid-19 infection. J Endocrinol Invest. 2020 Aug;43(8):1173-1174. doi: 10.1007/s40618-020-01316-3.

Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. Eur J Endocrinol. 2020 Oct;183(4):381-387. doi: 10.1530/EJE-20-0335.

Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ. 2020 Jul 6;192(27):E756-E767. doi: 10.1503/cmaj.200645.

Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020 Jun;582(7813):469. doi: 10.1038/d41586-020-01824-5.

RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436.

Freire Santana M, Borba MGS, Baía-da-Silva DC, et al. Case Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study. Am J Trop Med Hyg. 2020 Oct;103(4):1604-1607. doi: 10.4269/ajtmh.20-0787.

Iuga AC, Marboe CC, M Yilmaz M, Lefkowitch JH, Gauran C, Lagana SM. Adrenal Vascular Changes in COVID-19 Autopsies. Arch Pathol Lab Med. 2020 Oct 1;144(10):1159-1160. doi: 10.5858/arpa.2020-0248-LE.

Frankel M, Feldman I, Levine M, et al. Bilateral Adrenal Hemorrhage in Coronavirus Disease 2019 Patient: A Case Report. J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa487. doi: 10.1210/clinem/dgaa487.

Leow MK, Kwek DS, Ng AW, Ong KC, Kaw GJ, Lee LS. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin Endocrinol (Oxf). 2005 Aug;63(2):197-202. doi: 10.1111/j.1365-2265.2005.02325.x.

Freire Santana M, Borba MGS, Baía-da-Silva DC, et al. Case Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study. Am J Trop Med Hyg. 2020 Oct;103(4):1604-1607. doi: 10.4269/ajtmh.20-0787.

Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020 Oct;1(6):e245-e253. doi: 10.1016/S2666-5247(20)30115-4.

Ragnarsson O, Olsson DS, Chantzichristos D, et al. The incidence of Cushing's disease: a nationwide Swedish study. Pituitary. 2019 Apr;22(2):179-186. doi: 10.1007/s11102-019-00951-1.

Newell-Price J, Nieman LK, Reincke M, Tabarin A. Endocrinology in the time of COVID-19: Management of Cushing's syndrome. Eur J Endocrinol. 2020 Jul;183(1):G1-G7. doi: 10.1530/EJE-20-0352.

Moncet D, Morando DJ, Pitoia F, Katz SB, Rossi MA, Bruno OD. Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome. Medicina (B Aires). 2007;67(1):26-31.

Blevins LS Jr, Sanai N, Kunwar S, Devin JK. An approach to the management of patients with residual Cushing's disease. J Neurooncol. 2009 Sep;94(3):313-9. doi: 10.1007/s11060-009-9888-2.

Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet. 2015 Aug 29;386(9996):913-27. doi: 10.1016/S0140-6736(14)61375-1.

Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016 Jul;4(7):611-29. doi: 10.1016/S2213-8587(16)00086-3.

Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005 Aug 1;202(3):415-24. doi: 10.1084/jem.20050828.

Downloads

Published

2022-04-22

How to Cite

Kravchenko, V., Rakov, O., & Slipachuk, L. (2022). Hypercortisolism on the background of recovery of COVID-19 (сase report). INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 18(2), 133–137. https://doi.org/10.22141/2224-0721.18.2.2022.1159

Issue

Section

Clinical Case